Long non‑coding RNA CASC11 interacts with YBX1 to promote prostate cancer progression by suppressing the p53 pathway Corrigendum in /10.3892/ijo.2023.5593

Sun,Xianchao; Sun,Xianchao; Xin,Shiyong; Xin,Shiyong; Zhang,Ying; Zhang,Ying; Jin,Liang; Jin,Liang; Liu,Xiang; Liu,Xiang; Zhang,Jiaxin; Zhang,Jiaxin; Mei,Wangli; Mei,Wangli; Zhang,Bihui; Zhang,Bihui; Ma,Weiguo; Ma,Weiguo; Ye,Lin; Ye,Lin

doi:10.3892/ijo.2022.5400

Long non‑coding RNA CASC11 interacts with YBX1 to promote prostate cancer progression by suppressing the p53 pathway

Corrigendum in: /10.3892/ijo.2023.5593

Authors:
- Xianchao Sun
- Shiyong Xin
- Ying Zhang
- Liang Jin
- Xiang Liu
- Jiaxin Zhang
- Wangli Mei
- Bihui Zhang
- Weiguo Ma
- Lin Ye
View Affiliations

Affiliations: Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, P.R. China, Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Urology, Tongxin People's Hospital, Tongxin, Ningxia 751300, P.R. China
Published online on: July 27, 2022 https://doi.org/10.3892/ijo.2022.5400
Article Number: 110
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) is one of the principal causes of cancer‑related death worldwide. The roles and mechanisms of long non‑coding RNA (lncRNA) involved in the development of PCa remain incompletely understood. The present study aimed to investigate the role and mechanism of lncRNA in PCa tumorigenesis. In the present study, lncRNA cancer susceptibility candidate 11 (CASC11) was revealed to be a crucial regulator of PCa progression. The expression profiles of CASC11 in PCa were identified through analysis of The Cancer Genome Atlas and Gene Expression Omnibus datasets, and validated in human PCa specimens and cell lines. Gain‑ and loss‑of‑function assays were utilized to explore the biological role of CASC11 in PCa initiation and progression. RNA‑sequencing, RNA pull‑down and RNA immunoprecipitation analyses were used to explore potential mechanisms with which CASC11 may be associated. Rescue experiments were further conducted to confirm this association. The present results revealed that CASC11 was dominantly distributed in the nuclei of PCa cells, and was highly expressed in PCa tissues and cells. Overexpression of CASC11 was markedly associated with increased tumor proliferation and migratory ability. Functionally, decreased proliferation and migration, as well as inhibited xenograft tumor growth, were observed in CASC11‑silenced PCa cells, whereas the opposite effects were detected in CASC11‑overexpressing cells. Mechanistically, CASC11 promoted progression of the cell cycle and competitively interacted with Y‑box binding protein 1 (YBX1) to block the p53 pathway. Given this, poly (β‑amino ester) (PBAE)/small interfering RNA‑CASC11 (si‑CASC11) nanoparticles were applied to inhibit CASC11 expression and enhance the antitumor effect in vivo. The results revealed that PBAE/si‑CASC11 nanoparticles augmented the antitumor efficacy of CASC11 knockdown in vivo. In conclusion, the present study suggested that CASC11 may regulate PCa progression and elucidated a novel CASC11/YBX1/p53 signaling axis, providing a potential lncRNA‑directed therapeutic strategy particularly for the treatment of patients with PCa.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI
2	Marhold M, Kramer G, Krainer M and Le Magnen C: The prostate cancer landscape in Europe: Current challenges, future opportunities. Cancer Lett. 526:304–310. 2022. View Article : Google Scholar
3	Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T and Bristow RG: Prostate cancer. Nat Rev Dis Primers. 7:92021. View Article : Google Scholar : PubMed/NCBI
4	Zhu Y, Freedland SJ and Ye D: Prostate cancer and prostatic diseases best of asia, 2019: Challenges and opportunities. Prostate Cancer Prostatic Dis. 23:197–198. 2020. View Article : Google Scholar
5	Bridges MC, Daulagala AC and Kourtidis A: LNCcation: lncRNA localization and function. J Cell Biol. 220:e2020090452021. View Article : Google Scholar : PubMed/NCBI
6	Lang C, Yin C, Lin K, Li Y, Yang Q, Wu Z, Du H, Ren D, Dai Y and Peng X: m(6) A modification of lncRNA PCAT6 promotes bone metastasis in prostate cancer through IGF2BP2-mediated IGF1R mRNA stabilization. Clin Transl Med. 11. pp. e4262021, View Article : Google Scholar
7	Wu G, Hao C, Qi X, Nie J, Zhou W, Huang J and He Q: LncRNA SNHG17 aggravated prostate cancer progression through regulating its homolog SNORA71B via a positive feedback loop. Cell Death Dis. 11:3932020. View Article : Google Scholar : PubMed/NCBI
8	Ghildiyal R, Sawant M, Renganathan A, Mahajan K, Kim EH, Luo J, Dang HX, Maher CA, Feng FY and Mahajan NP: Loss of long noncoding RNA NXTAR in prostate cancer augments androgen receptor expression and enzalutamide resistance. Cancer Res. 82:155–168. 2022. View Article : Google Scholar
9	Wang B, Xu W, Hu C, Liu K, Chen J, Guo C and Yuan C: Critical roles of the lncRNA CASC11 in tumor progression and cancer metastasis: The biomarker and therapeutic target potential. Genes Dis. 9:325–333. 2022. View Article : Google Scholar :
10	Zhang Z, Zhou C, Chang Y, Zhang Z, Hu Y, Zhang F, Lu Y, Zheng L, Zhang W and Li X and Li X: Long non-coding RNA CASC11 interacts with hnRNP-K and activates the WNT/β-catenin pathway to promote growth and metastasis in colorectal cancer. Cancer Lett. 376:62–73. 2016. View Article : Google Scholar : PubMed/NCBI
11	Song H, Liu Y, Li X, Chen S, Xie R, Chen D, Gao H, Wang G, Cai B and Yang X: Long noncoding RNA CASC11 promotes hepatocarcinogenesis and HCC progression through EIF4A3-mediated E2F1 activation. Clin Transl Med. 10:e2202020. View Article : Google Scholar : PubMed/NCBI
12	Cheng N, Wu J, Yin M, Xu J, Wang Y, Chen X, Nie Z and Yin J: LncRNA CASC11 promotes cancer cell proliferation in hepatocellular carcinoma by inhibiting miRNA-188-5p. Biosci Rep. Apr 30–2019.Epub ahead of print. View Article : Google Scholar
13	Cui Y, Shen G, Zhou D and Wu F: CASC11 overexpression predicts poor prognosis and regulates cell proliferation and apoptosis in ovarian carcinoma. Cancer Manag Res. 12:523–529. 2020. View Article : Google Scholar : PubMed/NCBI
14	Capik O, Sanli F, Kurt A, Ceylan O, Suer I, Kaya M, Ittmann M and Karatas OF: CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis. Prostate Cancer Prostatic Dis. 24:891–902. 2021. View Article : Google Scholar : PubMed/NCBI
15	Humphrey PA, Moch H, Cubilla AL, Ulbright TM and Reuter VE: The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: Prostate and bladder tumours. Eur Urol. 70:106–119. 2016. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
17	Mao W, Wang K, Xu B, Zhang H, Sun S, Hu Q, Zhang L, Liu C, Chen S, Wu J, et al: ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma. Mol Cancer. 20:1422021. View Article : Google Scholar : PubMed/NCBI
18	Yan X, Pan Q, Xin H, Chen Y and Ping Y: Genome-editing prodrug: Targeted delivery and conditional stabilization of CRISPR-Cas9 for precision therapy of inflammatory disease. Sci Adv. 7:eabj06242021. View Article : Google Scholar : PubMed/NCBI
19	Mortensen MM, HØyer S, Lynnerup AS, Ørntoft TF, SØrensen KD, Borre M and Dyrskjøt L: Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Sci Rep. 5:160182015. View Article : Google Scholar : PubMed/NCBI
20	Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA and Sanda MG: Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res. 15:5794–5802. 2009. View Article : Google Scholar : PubMed/NCBI
21	Yang C, Xue Z, Liu Y, Xiao J, Chen J, Zhang L, Guo J and Lin W: Delivery of anticancer drug using pH-sensitive micelles from triblock copolymer MPEG-b-PBAE-b-PLA. Mater Sci Eng C Mater Biol Appl. 84:254–262. 2018. View Article : Google Scholar : PubMed/NCBI
22	Yamada Y and Beltran H: The treatment landscape of metastatic prostate cancer. Cancer Lett. 519:20–29. 2021. View Article : Google Scholar : PubMed/NCBI
23	Adamaki M and Zoumpourlis V: Prostate cancer biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther. 228:1079322021. View Article : Google Scholar : PubMed/NCBI
24	Hua JT, Chen S and He HH: Landscape of noncoding RNA in prostate cancer. Trends Genet. 35:840–851. 2019. View Article : Google Scholar : PubMed/NCBI
25	Tan YT, Lin JF, Li T, Li JJ, Xu RH and Ju HQ: LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond). 41:109–120. 2021. View Article : Google Scholar
26	Xu YH, Deng JL, Wang G and Zhu YS: Long non-coding RNAs in prostate cancer: Functional roles and clinical implications. Cancer Lett. 464:37–55. 2019. View Article : Google Scholar : PubMed/NCBI
27	Ahmad I, Fakhri S, Khan H, Jeandet P, Aschner M and Yu ZL: Targeting cell cycle by β-carboline alkaloids in vitro: Novel therapeutic prospects for the treatment of cancer. Chem Biol Interact. 330:1092292020. View Article : Google Scholar
28	Dyshlovoy SA, Tarbeeva D, Fedoreyev S, Busenbender T, Kaune M, Veselova M, Kalinovskiy A, Hauschild J, Grigorchuk V, Kim N, et al: Polyphenolic compounds from lespedeza bicolor root bark inhibit progression of human prostate cancer cells via induction of apoptosis and cell cycle arrest. Biomolecules. 10:4512020. View Article : Google Scholar :
29	Duffy MJ, Synnott NC, O'Grady S and Crown J: Targeting p53 for the treatment of cancer. Semin Cancer Biol. 79:58–67. 2022. View Article : Google Scholar
30	Kim MP, Li X, Deng J, Zhang Y, Dai B, Allton KL, Hughes TG, Siangco C, Augustine JJ, Kang Y, et al: Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov. 11:2094–2111. 2021. View Article : Google Scholar : PubMed/NCBI
31	Zhang A, Xu M and Mo YY: Role of the lncRNA-p53 regulatory network in cancer. J Mol Cell Biol. 6:181–191. 2014. View Article : Google Scholar : PubMed/NCBI
32	Mitra S, Muralidharan SV, Di Marco M, Juvvuna PK, Kosalai ST, Reischl S, Jachimowicz D, Subhash S, Raimondi I, Kurian L, et al: Subcellular distribution of p53 by the p53-responsive lncRNA NBAT1 determines chemotherapeutic response in neuroblastoma. Cancer Res. 81:1457–1471. 2021. View Article : Google Scholar
33	Chen Y, Hao Q, Wang S, Cao M, Huang Y, Weng X, Wang J, Zhang Z, He X, Lu H and Zhou X: Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP. Proc Natl Acad Sci USA. 118:e20268131182021. View Article : Google Scholar : PubMed/NCBI
34	Sanchez Y, Segura V, Marin-Bejar O, Athie A, Marchese FP, Gonzalez J, Bujanda L, Guo S, Matheu A and Huarte M: Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature. Nat Commun. 5:58122014. View Article : Google Scholar : PubMed/NCBI
35	Lyabin DN, Eliseeva IA and Ovchinnikov LP: YB-1 protein: Functions and regulation. Wiley Interdiscip Rev RNA. 5:95–110. 2014. View Article : Google Scholar
36	Gandhi M, Groß M, Holler JM, Coggins SA, Patil N, Leupold JH, Munschauer M, Schenone M, Hartigan CR, Allgayer H, et al: The lncRNA lincNMR regulates nucleotide metabolism via a YBX1-RRM2 axis in cancer. Nat Commun. 11:32142020. View Article : Google Scholar
37	Zheng X, Zhang J, Fang T, Wang X, Wang S, Ma Z, Xu Y, Han C, Sun M, Xu L, et al: The long non-coding RNA PIK3CD-AS2 promotes lung adenocarcinoma progression via YBX1-mediated suppression of p53 pathway. Oncogenesis. 9:342020. View Article : Google Scholar : PubMed/NCBI
38	Itsumi M, Shiota M, Sekino Y, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Kajioka S, Uchiumi T and Eto M: High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer. Prostate. 80:885–894. 2020. View Article : Google Scholar : PubMed/NCBI
39	Adams J, Casali A and Campbell K: Sensitive high-throughput assays for tumour burden reveal the response of a drosophila melanogaster model of colorectal cancer to standard chemotherapies. Int J Mol Sci. 22:51012021. View Article : Google Scholar :
40	Yari H, Gali H and Awasthi V: Nanoparticles for targeting of prostate cancer. Curr Pharm Des. 26:5393–5413. 2020. View Article : Google Scholar : PubMed/NCBI
41	Mezghrani B, Ali LMA, Richeter S, Durand JO, Hesemann P and Bettache N: Periodic mesoporous ionosilica nanoparticles for green light photodynamic therapy and photochemical internalization of siRNA. ACS Appl Mater Interfaces. 13:29325–29339. 2021. View Article : Google Scholar : PubMed/NCBI